Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
Rhea-AI Summary
Kodiak Sciences (Nasdaq: KOD) closed an underwritten public offering of 8,000,000 common shares, including 1,043,478 shares sold under the underwriters' full option exercise, at $23.00 per share.
The gross proceeds to Kodiak Sciences were approximately $184 million before underwriting discounts, commissions and estimated offering expenses. The offering used a shelf registration declared effective June 2, 2023, and the final prospectus supplement is filed with the SEC.
Joint book-running managers were J.P. Morgan, Jefferies, Evercore ISI and UBS Investment Bank. Management said the transaction strengthens the company’s financial position as it advances Phase 3 topline readouts for KSI-101, KSI-501 and tarcocimab.
Positive
- Gross proceeds of approximately $184 million
- Underwriters exercised 1,043,478 additional shares
- Offering priced at $23.00 per share
- Proceeds intended to support Phase 3 readouts for three assets
Negative
- Issued 8,000,000 new shares, increasing outstanding share count
- Offering proceeds reported net of underwriting discounts and expenses, reducing cash benefit
News Market Reaction – KOD
In the Dec 19 session, KOD declined 1.44%, reflecting a mild negative market reaction. Argus tracked a peak move of +2.0% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. Trading volume was very high at 4.0x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 16 | Equity offering pricing | Neutral | +4.8% | Priced upsized underwritten common stock offering at $23 per share. |
| Dec 15 | Equity offering proposed | Neutral | -3.3% | Announced proposed underwritten common stock offering with 30-day option. |
| Nov 13 | Earnings and outlook | Negative | -6.8% | Reported Q3 net loss, cash of $72M and ongoing late-stage trial spending. |
| Nov 12 | Investor conferences | Neutral | +3.2% | Announced CEO presentations at two upcoming healthcare investor conferences. |
| Nov 05 | Clinical data update | Positive | -1.5% | Released positive Week 20 KSI-101 APEX data with strong efficacy signals. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news shows mostly aligned price reactions, with a single divergence where positive clinical data was followed by a modest decline.
Over the last two months, Kodiak has balanced late-stage clinical progress with financing needs. A Nov 5 Phase 1b KSI-101 update showed strong vision and fluid outcomes, yet shares slipped. The Nov 13 Q3 results highlighted sizeable losses and going-concern risk, and the stock fell further. In mid-December, a sequence of proposed and upsized equity offerings led to mixed, mostly aligned moves as investors digested dilution alongside funding for multiple Phase 3 programs.
Key Terms
underwritten public offering financial
prospectus supplement regulatory
prospectus regulatory
Phase 3 medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
J.P. Morgan, Jefferies, Evercore ISI and UBS Investment Bank acted as joint book-running managers for the offering.
Dr. Victor Perlroth, M.D., Chairman and CEO of Kodiak commented, "we are pleased to have successfully completed this public offering, which strengthens our financial position as we execute through important Phase 3 topline readouts for all three of our late-stage clinical assets of KSI-101, KSI-501 and tarcocimab. The transaction was thoughtfully structured, reflecting our disciplined approach to capital formation and our continued focus on long-term shareholder value."
The shares described above were offered by Kodiak Sciences pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed by Kodiak Sciences with the Securities and Exchange Commission (the "SEC") and that was declared effective by the SEC on June 2, 2023. A final prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available for free on the SEC's website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue,
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Kodiak Sciences Inc.
Kodiak Sciences (Nasdaq: KOD) is a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC® Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies and has been at the core of Kodiak's discovery engine. We are developing a portfolio of three late-stage clinical programs. Tarcocimab and KSI-501 are being explored in two BLA-facing Phase 3 studies in the retinal vascular diseases. KSI-101 is a bispecific protein being explored in two Phase 3 studies in Macular Edema Secondary to Inflammation (MESI).
Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.
View original content:SOURCE Kodiak Sciences Inc.